Biomagnetics Completes Audit and Financial Review

SAN FRANCISCO--(BUSINESS WIRE)-- Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced the completion of its full audit and financial review, which was conducted by Seale & Beers Certified Public Accounts, LLC.

"I am pleased that the audit has now been completed and that we are moving toward full reporting status with the U.S. Securities & Exchange Commission. We are excited about the future for Biomagnetics and we want to make sure all of our investors and shareholders have full transparency into our operations," commented Clayton Hardman, CEO of Biomagnetics.

About Biomagnetics Diagnostics Corp.

Biomagnetics Diagnostics Corporation is an advanced medical device and biotechnology company and an acquirer of other innovative technologies. More information on Biomagnetics Diagnostics Corp. can be seen at www.biomagneticsbmgp.com.



CONTACT:

Biomagnetics Diagnostics Corp.
Joe Noel, 925-922-2560

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Medical Devices

MEDIA:

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.